Vaccine Development: How 2bind Used Accelerated Stability Studies To Optimize An Antigen For HIV-Vaccine Research

Join Dr. Thomas Schubert, CEO of 2bind, as he walks through information from the Prometheus Panta that helped them select the optimal buffer for a vaccine antigen.

You’ll learn about:

• Why 2bind required both thermal and colloidal stability information to identify the optimal buffer for antigen stability out of a 96 condition screen
• Which stress conditions they assessed to probe the limits of antigen stability in the selected buffer, and how DLS helped them do it
• How they further used DLS to validate epitope integrity and antibody binding to the antigen
• How the group used a single instrument to conduct all their experiments for buffer optimization